ArticleTherapeutic innovation & regulatory science2025
Navigating the Trends in USFDA Authorized Generic Approvals (2019-2024): Enhancing Healthcare Accessibility and Affordability.
Article in Therapeutic innovation & regulatory science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study examines trends in USFDA's authorized generic (AG) approvals from January 2019 to August 2024, focusing on approval patterns, leading therapeutic areas, dominant dosage forms, and key companies. The research aims to highlight market dynamics and the role of AGs in enhancing healthcare accessibility and affordability with case studies.
methodsData was collected from the FDA's list of authorized generic drugs and analyzed to identify trends in annual approvals, therapeutic areas, and dosage forms. A company-wise analysis was conducted to identify top performers, with a detailed evaluation of their approval trends and strategic focus areas across therapeutic categories. Recent case studies of AGs were included to explore their clinical and economic significance. The impact of the Inflation Reduction Act, Continuing Appropriations Act, of 2020, and Health Extenders Act of 2019 on the definition and pricing of AGs, as well as its implications for the pharmaceutical industry and Medicaid Drug Rebate Program, were examined.
resultsAG approvals peaked in 2019 (31%) and 2020 (33%), then declined. Leading therapeutic areas were cardiovascular (18%), neurology (14%), and endocrinology (13%). Tablets comprised 35% of approvals, followed by capsules (23%) and solutions (9%). GlaxoSmithKline led with 7% of approvals, primarily in pulmonology and migraine, while Bausch Health (6.25%) focused on dermatology and endocrinology. IBSA Pharma (5.47%) excelled in endocrinology and pain management. Pfizer and Cediprof each had 4.69%, with Pfizer focusing on cardiovascular and infectious diseases, and Cediprof specializing in endocrinology. Recent case studies of AGs provided an affordable, effective alternative for diabetes and cardiovascular care.
conclusionAGs effectively bridge the transition from branded to generic drugs, supporting broader access to treatment, cost efficiency, and ongoing innovation in the pharmaceutical sector. The analysis highlights AGs' significant role in addressing healthcare needs while underscoring challenges like exclusivity agreements and profit constraints for traditional generics. These findings affirm AGs as pivotal in advancing pharmaceutical market dynamics and healthcare affordability.
Indexed as
Identifiers
40402352What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.